期刊
TRANSFUSION
卷 58, 期 9, 页码 2202-2207出版社
WILEY
DOI: 10.1111/trf.14652
关键词
-
类别
资金
- Deutsche Forschungsgemeinschaft der Blutspendedienste des Deutschen Roten Kreuzes
- Macopharma S.A.S.
BACKGROUNDEbola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have been identified as potential threats to blood safety. This study investigated the efficacy of the THERAFLEX UV-Platelets and THERAFLEX MB-Plasma pathogen inactivation systems to inactivate EBOV and MERS-CoV in platelet concentrates (PCs) and plasma, respectively. STUDY DESIGN AND METHODSPCs and plasma were spiked with high titers of cell culture-derived EBOV and MERS-CoV, treated with various light doses of ultravioletC (UVC; THERAFLEX UV-Platelets) or methylene blue (MB) plus visible light (MB/light; THERAFLEX MB-Plasma), and assessed for residual viral infectivity. RESULTSUVC reduced EBOV (4.5 log) and MERS-CoV (3.7 log) infectivity in PCs to the limit of detection, and MB/light decreased EBOV (4.6 log) and MERS-CoV (3.3 log) titers in plasma to nondetectable levels. CONCLUSIONSBoth THERAFLEX UV-Platelets (UVC) and THERAFLEX MB-Plasma (MB/light) effectively reduce EBOV and MERS-CoV infectivity in platelets and plasma, respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据